Vynfinit progress sees near doubling of Endocyte value
This article was originally published in Scrip
Investors responded enthusiastically to two positive pieces of news from Endocyte on Friday 21 March. First, experts on the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM) recommended granting conditional marketing authorisation for Vynfinit (vintafolide) to treat women with a sub-type of platinum-resistant ovarian cancer for which there are limited approved treatment options. Second, the company reported that in the Phase IIb TARGET trial, Vynfinit plus docetaxel, as a potential second-line treatment of non-small cell lung cancer (NSCLC), met the primary endpoint of improving progression free survival versus docetaxel alone.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.